药康生物
(688046)
| 流通市值：80.11亿 | | | 总市值：80.11亿 |
| 流通股本：4.10亿 | | | 总股本：4.10亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 415,147,269.66 | 486,620,728.45 | 304,333,782.27 | 522,037,439.43 |
| 交易性金融资产 | 670,480,086.84 | 757,693,494.32 | 894,153,632.16 | 670,253,369.98 |
| 应收票据及应收账款 | 425,599,216.78 | 384,962,303.74 | 426,696,176.99 | 415,219,261.85 |
| 应收账款 | 425,599,216.78 | 384,962,303.74 | 426,696,176.99 | 415,219,261.85 |
| 预付款项 | 9,243,175.4 | 7,205,818.97 | 9,239,887.91 | 5,396,397.68 |
| 其他应收款合计 | 4,689,142.76 | 4,239,335.82 | 4,855,992.23 | 5,393,009.06 |
| 存货 | 86,840,183.99 | 72,961,120.3 | 69,474,356.56 | 62,563,165.24 |
| 一年内到期的非流动资产 | - | - | - | 22,098,876.52 |
| 其他流动资产 | 99,354,010.73 | 37,790,878.92 | 82,564,918.91 | 78,799,195.87 |
| 流动资产平衡项目 | 0.01 | 0 | 0 | 0 |
| 流动资产合计 | 1,711,353,086.17 | 1,751,473,680.52 | 1,791,318,747.03 | 1,781,760,715.63 |
| 非流动资产: | | | | |
| 长期股权投资 | 79,007,170.53 | 88,812,314.68 | 90,657,541.33 | 91,625,786.27 |
| 其他权益工具投资 | 10,794,420 | 10,794,420 | 10,499,952 | 8,999,952 |
| 其他非流动金融资产 | 10,061,643.84 | 10,000,000 | 10,191,095.92 | 10,128,082.21 |
| 固定资产 | 568,061,353.27 | 573,246,662.51 | 470,113,636.49 | 477,741,529.49 |
| 在建工程 | 24,767,345.38 | 22,460,943.33 | 118,655,229.71 | 112,267,165.55 |
| 生产性生物资产 | 7,018,983.74 | 7,333,557.34 | 7,270,802.77 | 7,113,947.75 |
| 使用权资产 | 85,285,329.73 | 90,683,728.51 | 58,045,140.67 | 58,910,426.23 |
| 无形资产 | 72,052,454.49 | 71,371,542.72 | 49,045,460.28 | 47,564,498.8 |
| 开发支出 | 3,754,291.56 | 3,754,291.56 | 10,058,684.64 | 9,361,527.76 |
| 长期待摊费用 | 23,173,557.84 | 24,723,086.04 | 26,363,243.08 | 29,378,185.08 |
| 递延所得税资产 | 33,474,709.04 | 33,138,894.25 | 41,688,423.19 | 39,599,537.13 |
| 其他非流动资产 | 239,233,784.34 | 177,273,690.01 | 146,147,981.6 | 124,039,048.13 |
| 非流动资产合计 | 1,156,685,043.76 | 1,113,593,130.95 | 1,038,737,191.68 | 1,016,729,686.4 |
| 资产总计 | 2,868,038,129.93 | 2,865,066,811.47 | 2,830,055,938.71 | 2,798,490,402.03 |
| 流动负债: | | | | |
| 短期借款 | 158,186,638.4 | 187,325,204.71 | 255,366,399.06 | 240,589,606.23 |
| 应付票据及应付账款 | 71,081,683.56 | 68,133,909.91 | 67,683,970.35 | 64,809,103.29 |
| 应付账款 | 71,081,683.56 | 68,133,909.91 | 67,683,970.35 | 64,809,103.29 |
| 合同负债 | 172,982,805.73 | 176,398,259 | 147,802,147.91 | 134,238,146.53 |
| 应付职工薪酬 | 29,106,972.99 | 52,523,918.63 | 39,783,564.9 | 33,279,578.35 |
| 应交税费 | 15,212,330.55 | 11,440,614.24 | 11,336,509.44 | 7,549,826.24 |
| 其他应付款合计 | 6,678,011.09 | 7,569,704.57 | 6,438,135.65 | 51,385,161.63 |
| 应付股利 | - | - | - | 44,988,970.18 |
| 一年内到期的非流动负债 | 24,374,866.44 | 23,752,541.69 | 14,152,221.69 | 11,906,543.29 |
| 流动负债平衡项目 | -0.01 | 0 | 0.01 | 0 |
| 流动负债合计 | 477,623,308.75 | 527,144,152.75 | 542,562,949.01 | 543,757,965.56 |
| 非流动负债: | | | | |
| 租赁负债 | 76,951,952.29 | 80,234,045.76 | 57,879,715.8 | 57,317,990.93 |
| 递延收益 | 26,857,138.16 | 22,562,058.89 | 18,820,131.19 | 20,493,001.11 |
| 递延所得税负债 | 7,721,033.06 | 7,929,400.5 | 9,746,814.17 | 9,009,276.04 |
| 非流动负债合计 | 111,530,123.51 | 110,725,505.15 | 86,446,661.16 | 86,820,268.08 |
| 负债合计 | 589,153,432.26 | 637,869,657.9 | 629,009,610.17 | 630,578,233.64 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 410,000,000 | 410,000,000 | 410,000,000 | 410,000,000 |
| 资本公积 | 1,256,297,725.59 | 1,253,186,839.59 | 1,253,258,796.39 | 1,251,028,660.71 |
| 减:库存股 | 16,017,183.67 | 16,017,183.67 | 22,903,999.33 | 14,730,302.94 |
| 其他综合收益 | 8,545,424.93 | 7,072,562.75 | 8,167,178.3 | 8,084,054.89 |
| 盈余公积 | 62,310,381.53 | 62,310,381.53 | 52,305,892.22 | 52,305,892.22 |
| 未分配利润 | 557,748,349.29 | 510,644,553.37 | 500,218,460.96 | 461,223,863.51 |
| 归属于母公司股东权益合计 | 2,278,884,697.67 | 2,227,197,153.57 | 2,201,046,328.54 | 2,167,912,168.39 |
| 股东权益合计 | 2,278,884,697.67 | 2,227,197,153.57 | 2,201,046,328.54 | 2,167,912,168.39 |
| 负债和股东权益合计 | 2,868,038,129.93 | 2,865,066,811.47 | 2,830,055,938.71 | 2,798,490,402.03 |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-23 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |